Kura Oncology Inc and Kyowa Kirin Co Ltd Strategic Collaboration Presentation Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Jonathan Chang - Leerink Partners LLC - Analyst : Hi, guys. Congrats on the deal and thanks for taking my question. I guess just, what I want to understand is, can you discuss the high-level rationale behind this partnership versus other potential avenues, Troy? And I guess, why now versus later?

Question: Jonathan Chang - Leerink Partners LLC - Analyst : Understood. Thanks for taking my question.

Question: Alexa Deemer - Cantor Fitzgerald - Analyst : Hi, this is Alexa Deemer on for Li Watsek. I just wanted to start off by saying congratulations on this exciting opportunity. And my question is, for the $420 million in near-term milestones, can you elaborate a little more on the breakdown of approval milestones versus launch milestones?

Question: Alexa Deemer - Cantor Fitzgerald - Analyst : Okay, thank you.

Question: Roger Song - Jefferies LLC - Analyst : Great. Congrats, adding our congratulations to the deal. Maybe two quick questions from us, the first one is, given the last time you show us some data early this year, and then you were about to show the data at ASH, so how much the data sharing you have gotten with -- have shared with Kirin, the partner? And the second question is, given Kirin has a very strong presence ex-US, how should we think about the ex-US sales versus US sales in the future, the potential? Thank you.

Question: Roger Song - Jefferies LLC - Analyst : Thank you. REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. NOVEMBER 20, 2024 / 10:30PM, KURA.OQ - Kura Oncology Inc and Kyowa Kirin Co Ltd Strategic Collaboration Presentation

Question: Peter Lawson - Barclays Capital Inc. - Analyst : Great, thank you so much. I guess, a couple of questions, firstly, with the funding, Troy, if this has accelerated any programs or if you view this as a way of accelerating enrollment, and how you think this has kind of changed your ability to get to market.

Question: Peter Lawson - Barclays Capital Inc. - Analyst : Okay, perfect. Thank you. And, Troy, I apologize, I may have missed this, but your partner, Kyowa, what did they see? Did they see the frontline or the pivotal data?

Question: Peter Lawson - Barclays Capital Inc. - Analyst : Great. Thank you so much. REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. NOVEMBER 20, 2024 / 10:30PM, KURA.OQ - Kura Oncology Inc and Kyowa Kirin Co Ltd Strategic Collaboration Presentation

Question: Reni Benjamin - Citizens JMP Securities, LLC - Analyst : Hey, guys. Thanks for taking my questions, and congratulations on a really nice deal, and having the funding now available to run all your studies. A couple of questions for me, Troy, I guess -- one, you had mentioned in your prepared remarks that you're retaining key strategic rights of zifto in the US. But by looking at the deal, it seems like everything has kind of been given out, so I'm kind of curious if you can provide some more color as to what those key strategic rights are. And maybe just related to that, will there be a joint committee that you can utilize Kyowa Kirin's expertise in designing new clinical trials going forward or is it really kind of a silent partner who's kind of letting you run the studies here in the US?

Question: Reni Benjamin - Citizens JMP Securities, LLC - Analyst : Yeah. No, that was. Thank you for that. Maybe just a quick question for the Kyowa team, can you talk a little bit about what your plans are for ex-US trials? When do you think they start? And would you be able to comment on what you think might be the first ex-US countries for potential commercialization? Thank you.

Question: Reni Benjamin - Citizens JMP Securities, LLC - Analyst : Thank you, Abdul. That's great.

Question: Joseph Pantginis - H.C. Wainwright & Co., LLC - Analyst : Hey, everybody, nice job. I just want to leave it there. But I guess, two questions, if you don't mind. So looking forward right now with regard to some of the use of the upfronts or what have you, as you approach KOMET-017, where do you stand on your manufacturing needs? And then I have a follow-up.

Question: Joseph Pantginis - H.C. Wainwright & Co., LLC - Analyst : No, I appreciate that. And I don't know if you could give any details here, but with regard to the opt-in for solid tumors, can you talk about what would be needed to trigger the opt-in? Is it after a time? After a particular data release? And let's just say if Kyowa Kirin does not opt in, it's then available for others?

Question: Joseph Pantginis - H.C. Wainwright & Co., LLC - Analyst : Understood. Thank you very much for the details.

Question: Philip Nadeau - TD Cowen - Analyst : Good afternoon. Thanks for taking our questions. Let us add our congratulations on the deal. Actually, a couple for Abdul, if that's okay, Abdul, we're curious to get your assessment of the menin opportunity. The slides today talk a lot about the frontline opportunity. Is that really the driving force behind the deal and the valuation? I guess, what's the relative contribution of frontline versus the relapsed/refractory space as you sign the opportunity? That's first. And then second, as I'm sure you're aware, the investment community has a multiyear debate about the competitive position of all the different menins that are in development. Curious to get your assessment of why Kura, how do you see the competitive environment. Thanks.

Question: Philip Nadeau - TD Cowen - Analyst : That was very helpful. Thanks for taking our questions and congrats again on getting the deal done.

Question: Justin Zelin - BTIG LLC - Analyst : Thanks for taking our questions and congrats on the partnership as well. Troy, I just wanted to ask about the development costs here. It looks like Kura's funding development costs through '28 and '29 onwards will be split at a 50-50. And just, which trials you think might be in that '29 onward time frame? I think you mentioned post-transplant maintenance might be one candidate there.

Question: Justin Zelin - BTIG LLC - Analyst : Understood. And with this deal, you mentioned that you're funding the rest of the pipeline. Any particular program or milestone that you're most excited about near-term that you think investors should focus on? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. NOVEMBER 20, 2024 / 10:30PM, KURA.OQ - Kura Oncology Inc and Kyowa Kirin Co Ltd Strategic Collaboration Presentation

Question: Justin Zelin - BTIG LLC - Analyst : Thanks for taking our questions and congrats again.

Question: George Farmer - Scotia Capital (USA) Inc. - Analyst : Hi, thanks for taking my question. Troy, I was wondering if you could comment on your plans to run the KOMET-017 as a company-sponsored trial. Your competitors going -- one of your competitors is going with a cooperative group to do this. Like, why? I mean, what are the different pluses and minuses when choosing between one or the other?

Question: George Farmer - Scotia Capital (USA) Inc. - Analyst : Okay, great. That's very helpful. And then one more, if I may, maybe Abdul from Kyowa Kirin can respond. I know you mentioned this frontline opportunity is really where the heart of this deal comes from. Are there plans to develop the drug in the relapsed/refractory setting as a single agent outside of the US?

Question: George Farmer - Scotia Capital (USA) Inc. - Analyst : Sure. Okay, thanks very much.